Abstract 371P
Background
Heterogeneous nature and poor prognosis of stage III NSCLC, accounting for ≈29% of NSCLC burden, cause substantial management challenges in India. We present the results of Indian cohort from the real-world, multicountry, observational KINDLE study that explored treatment patterns and associated outcomes in the pre-immuno-oncology era.
Methods
Retrospective data from 15 sites in India were analyzed for stage III NSCLC patients diagnosed between 01Jan2013 and 31Dec2017 with at least 9 months (m) of documented follow-up. Descriptive analyses for demographics, clinical characteristics, and treatment modalities, and inferential statistics to correlate treatment with progression-free survival (PFS) and overall survival (OS) were conducted.
Results
Data for 494 patients: median age 60.0 years (range 25-84), 83.4% men, 58.7% current/former smokers, and 48.2% and 51.8% with stage IIIA and IIIB NSCLC (AJCC 7th ed.), respectively; 84.9% had ECOG performance score of 0/1 at diagnosis. Squamous cell and adenocarcinoma represented 48.5% and 44.6%, respectively; 15.4% had EGFR mutations. Of the 18 first-line treatment modalities, the most frequent were concurrent chemoradiotherapy (cCRT) (29.5%), sequential CRT (13.6%), chemotherapy (CT) alone (13.3%), and radiotherapy alone (12.7%). Overall median PFS was 16.4m, 95% confidence interval (CI) 14.36-19.38 (stage IIIA: 19.4m, 95% CI 15.08-25.95; IIIB: 15.4m, 95%CI 12.45-19.78). Overall median OS was 66m, 95% CI 49.81-noncalculable (NC); (stage IIIA: NC, 95% CI 52.14-NC; IIIB 66.0m, 95% CI 36.04-NC). In stage IIIA patients, cCRT was associated with longer OS than CT alone (64.1m vs. 30.0m, p=0.0493). Among stage IIIB patients, cCRT was associated with significantly higher OS than CT alone (66.0m vs. 22.6m, p=0.0226).
Conclusions
The India data reveal varied treatment modalities in stage III NSCLC. Overall median PFS and OS were better for India (16.4m and 66m) than in the global cohort (12.5m and 34.9m). cCRT was associated with improved survival in both stage IIIA and IIIB. Improved access to newer medicines and quality care will be key to further enhance patient outcomes.
Clinical trial identification
Protocol - D133HR00004 NCT03725475.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
A. Kumar, R. Huggenberger, S. Robb: Full/Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session
339P - Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation: A phase III study
Presenter: Vikas Talreja
Session: e-Poster Display Session
340P - Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
Presenter: Alfredo Chua
Session: e-Poster Display Session
341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy
Presenter: Andree Kurniawan
Session: e-Poster Display Session
342P - Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer
Presenter: Satoshi Horasawa
Session: e-Poster Display Session
343P - Head-to-head comparison of palonosetron versus granisetron for prevention of chemotherapy induced nausea and vomiting: Systematic review and meta-analysis
Presenter: Chin-Hung Hsu
Session: e-Poster Display Session
344P - Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Presenter: Kohei Fujita
Session: e-Poster Display Session
345P - Thromboembolic events in brain tumour patients on bevacizumab
Presenter: Gunjesh Singh
Session: e-Poster Display Session
346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Presenter: Susanna Hutajulu
Session: e-Poster Display Session
347P - Histamine blockade with loratadine for prevention of granulocyte-colony stimulating factor (G-CSF)-associated bone pain: A meta-analysis
Presenter: Mel Valerie Ordinario
Session: e-Poster Display Session